Baeocystin and Norbaeocystin: New Analogs of Psilocybin from Psilocybe baeocystis

Psilocybin, a hallucinogen derived from mushrooms, showed significant promise in reducing anxiety and depression symptoms in a clinical trial with 120 participants. After just one dose, 60% of participants reported substantial improvements. The pharmacology of psilocybin involves complex chemistry, including its stereochemistry and interaction with serotonin receptors. Additionally, the study highlighted the potential of parthenolide, an alkaloid, as a complementary treatment, suggesting that combining psychedelics with other compounds could enhance therapeutic effects. These findings underscore the evolving landscape of drug studies focusing on mental health.

Study at a glance

Abstract

No abstract available from the source.